

Highlights of This Issue vii

SPOTLIGHT ON MOLECULAR PROFILING

- 257 **Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set**
Eun Sung Park, Rosalia Rabinovsky, Mark Carey, Bryan T. Hennessy, Roshan Agarwal, Wenbin Liu, Zhenlin Ju, Wanleng Deng, Yiling Lu, Hyun Goo Woo, Sang-Bae Kim, Jae-Ho Cheong, Levi A. Garraway, John N. Weinstein, Gordon B. Mills, Ju-Seog Lee, and Michael A. Davies

REVIEW

- 268 **Aurora Kinase Inhibitors—Rising Stars in Cancer Therapeutics?**
Altaf A. Dar, Laura W. Goff, Shahana Majid, Jordan Berlin, and Wael El-Rifai

RESEARCH ARTICLES

- 279 **Molecular Evolutionary Analysis of Cancer Cell Lines**
Yan Zhang, Michael J. Italia, Kurt R. Auger, Wendy S. Halsey, Stephanie F. Van Horn, Ganesh M. Sathe, Michal Magid-Slav, James R. Brown, and Joanna D. Holbrook
- 292 **Resistance to ErbB2 Tyrosine Kinase Inhibitors in Breast Cancer Is Mediated by Calcium-Dependent Activation of RelA**
Wenle Xia, Sarah Bacus, Intisar Husain, Leihua Liu, Sumin Zhao, Zuguo Liu, M. Arthur Moseley III, J. Will Thompson, Franklin L. Chen, Kevin M. Koch, and Neil L. Spector
- 300 **The Novel, Proteasome-Independent NF- κ B Inhibitor V1810 Induces Apoptosis and Cell Cycle Arrest in Multiple Myeloma and Overcomes NF- κ B-Mediated Drug Resistance**
Felix G. Meinel, Sonja Mandl-Weber, Philipp Baumann, Johann Leban, and Ralf Schmidmaier

- 311 **A Fine-Needle Aspirate-Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer**
Antonio Jimeno, Belen Rubio-Viqueira, N.V. Rajeshkumar, Audrey Chan, Anna Solomon, and Manuel Hidalgo
- 319 **Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation**
Jurjen S. Lagas, Robert A.B. van Waterschoot, Rolf W. Sparidans, Els Wagenaar, Jos H. Beijnen, and Alfred H. Schinkel
- 327 **Human Mutations That Confer Paclitaxel Resistance**
Shanghai Yin, Rajat Bhattacharya, and Fernando Cabral
- 336 **Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth**
Ping Zhang, Anju Singh, Srinivasan Yegnasubramanian, David Esopi, Ponvijay Kombairaju, Manish Bodas, Hailong Wu, Steven G. Bova, and Shyam Biswal
- 347 **ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors**
Chris T. Williamson, Huong Muzik, Ali G. Turhan, Alberto Zamò, Mark J. O'Connor, D. Gwyn Bebb, and Susan P. Lees-Miller
- 358 **Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination**
Pierre Mordant, Johann Lorient, Céline Leteur, Julien Calderaro, Jean Bourhis, Marie Wislez, Jean-Charles Soria, and Eric Deutsch

- 369 **The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases**
Rajeev S. Bhide, Louis J. Lombardo, John T. Hunt, Zhen-wei Cai, Joel C. Barrish, Susan Galbraith, Robert Jeyaseelan, Sr., Steven Mortillo, Barri S. Wautlet, Bala Krishnan, Daniel Kukral, Harold Malone, Anne C. Lewin, Benjamin J. Henley, and Joseph Fargnoli
- 379 **ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth**
Dianne Mitchell, Eileen G. Pobre, Aaron W. Mulivor, Asya V. Grinberg, Roselyne Castonguay, Travis E. Monnell, Nicolas Solban, Jeff A. Ucran, R. Scott Pearsall, Kathryn W. Underwood, Jasbir Seehra, and Ravindra Kumar
- 389 **Herbal Compound Farnesiferol C Exerts Antiangiogenic and Antitumor Activity and Targets Multiple Aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) Signaling Cascades**
Jae-Ho Lee, Sun Choi, Yoonji Lee, Hyo-Jeong Lee, Kwan-Hyun Kim, Kyoo-Seok Ahn, Hyunsoo Bae, Hyo-Jung Lee, Eun-Ok Lee, Kwang-Seok Ahn, Shi Yong Ryu, Junxuan Lü, and Sung-Hoon Kim
- 400 **Biochemical Characterization of AMG 102: A Neutralizing, Fully Human Monoclonal Antibody to Human and Nonhuman Primate Hepatocyte Growth Factor**
Teresa L. Burgess, Jan Sun, Susanne Meyer, Trace S. Tsuruda, Jilin Sun, Gary Elliott, Qing Chen, Mitsuru Haniu, Will F. Barron, Todd Juan, Ke Zhang, Angela Coxon, and Richard L. Kendall
- 410 **A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts**
Yaolin Wang, Philip Lipari, Xiaoying Wang, Judith Hailey, Lianzhu Liang, Robert Ramos, Ming Liu, Jonathan A. Pachter, W. Robert Bishop, and Yan Wang
- 419 **Ligand-Specific Antibodies to Insulin-Like Growth Factors Suppress Intestinal Polyp Formation in *Apc*^{+/-} Mice**
Toshihiro Matsunaka, Shin'ichi Miyamoto, Kenya Shitara, Atsushi Ochiai, and Tsutomu Chiba
- 429 **Identification of a Novel Raf-1 Pathway Activator that Inhibits Gastrointestinal Carcinoid Cell Growth**
Mackenzie R. Cook, Scott N. Pinchot, Renata Jaskula-Sztul, Jie Luo, Muthusamy Kunnimalaiyaan, and Herbert Chen
- 438 **Reprogramming Murine Telomerase Rapidly Inhibits the Growth of Mouse Cancer Cells *In vitro* and *In vivo***
Tong Xu, Yucheng Xu, Chun-Peng Liao, Roy Lau, and Amir Goldkorn
- 450 **A Novel E1B-55kD-Deleted Oncolytic Adenovirus Carrying Mutant KRAS-Regulated *hdm2* Transgene Exerts Specific Antitumor Efficacy on Colorectal Cancer Cells**
Chin-Cheng Liu, Jin-Hwang Liu, Suh-Chin Wu, Chueh-Chuan Yen, Wei-Shone Chen, and Ying-Chieh Tsai
- 461 **Gossypol Induces Apoptosis by Activating p53 in Prostate Cancer Cells and Prostate Tumor-Initiating Cells**
Suresh R. Volate, Brian T. Kawasaki, Elaine M. Hurt, John A. Milner, Young S. Kim, Jeffrey White, and William L. Farrar
- 471 **Restoration of p53 Functions Protects Cells from Concanavalin A-Induced Apoptosis**
A.R.M. Ruhul Amin, Vijay S. Thakur, Kalpana Gupta, Mark W. Jackson, Hisashi Harada, Mukesh K. Agarwal, Dong M. Shin, David N. Wald, and Munna L. Agarwal
- 480 **Caffeine Confers Radiosensitization of *PTEN*-Deficient Malignant Glioma Cells by Enhancing Ionizing Radiation-Induced G₁ Arrest and Negatively Regulating Akt Phosphorylation**
Brigitte Sinn, Gesche Tallen, Gisela Schroeder, Birgit Grassl, Joern Schulze, Volker Budach, and Inge Tinhofer
- 489 **Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors**
Holly K. Koblisch, Michael J. Hansbury, Kevin J. Bowman, Gengjie Yang, Claire L. Neilan, Patrick J. Haley, Timothy C. Burn, Paul Waeltz, Richard B. Sparks, Eddy W. Yue, Andrew P. Combs, Peggy A. Scherle, Kris Vaddi, and Jordan S. Fridman

Hormonal Regulation and Distinct Functions of Semaphorin-3B and Semaphorin-3F in Ovarian Cancer


Doina Joseph, Shuk-Mei Ho, and Viqar Syed

Interleukin-29 Binds to Melanoma Cells Inducing Jak-STAT Signal Transduction and Apoptosis

Kristan D. Guenterberg, Valerie P. Grignol, Ene T. Raig, Jason M. Zimmerer, Anthony N. Chan, Farriss M. Blaskovits, Gregory S. Young, Gerard J. Nuovo, Bethany L. Mundy, Gregory B. Lesinski, and William E. Carson III

ABOUT THE COVER

Lapatinib is a potent small-molecule inhibitor of the ErbB2 and EGFR tyrosine kinases. In ErbB2 overexpressing breast cancer cell lines, lapatinib unexpectedly activated the antiapoptotic mediator RelA/NF- κ B, which was shown to play a functional role in promoting the development of therapeutic resistance to lapatinib. Using immunohistochemical staining, it was found that tumor expression of phosphorylated RelA increased in a subset of ErbB2 overexpressing breast cancer patients who were treated with lapatinib monotherapy, which correlated with a poorer response to therapy. For more details, see article by Xia and colleagues on page 292.



Molecular Cancer Therapeutics

9 (2)

Mol Cancer Ther 2010;9:vii-520.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/9/2>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://mct.aacrjournals.org/content/9/2>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.